PLOS ONE | https://doi.org/10.1371/journal.pone.0183180 October 9, 2017
Cancer, diabetes, heart disease and stroke, chronic respiratory disease
AIDS Behav (2017) 21:S23–S33 DOI 10.1007/s10461-016-1670-9
Public Health Factsheet
Accessed: 29.09.2019
BMJ,Dodd PJ, et al. Thorax 2017;72:559–575. doi:10.1136/thoraxjnl-2016-209421
Good practice examples from India
Technical Report
AIDS Medicines and diagnostics service
September 2016
Topics in Antiviral Medicine 25 Issue 2 May/June 2017
Rutstein SE et al. Journal of the International AIDS Society 2017, 20:21579 http://www.jiasociety.org/index.php/jias/article/view/21579 | http://dx.doi.org/10.7448/IAS.20.1.21579
The toolkit is a collection of assessment tools and checklists that describe the key considerations to be taken into account when transitioning to Option B/B+. The toolkit provides a roadmap to support the planning and implementation of Option B/B+, and to help countries scale up more effective inte...rventions and programs to achieve the goals of the Global Plan Towards the Elimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive.
more
In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems’ ability to prov...ide population-wide access to essential medicines.
Pharmaceutical pricing policies need to be carefully planned, carried out, and regularly checked and revised according to changing conditions. Strong, well-thought-out policies can guide well-informed and balanced decisions to achieve affordable access to essential health products.
This guideline replaces the 2015 WHO guideline on country pharmaceutical pricing policies, revised to reflect the growing body of literature since the last evidence review in 2010. This update also recognizes country experiences in managing the prices of pharmaceutical products.
more